Travelers Reports Excellent First Quarter Results
First Quarter 2024 Net Income per Diluted Share of $4.80, up 16%, and Return on Equity of 18.0% First Quarter 2024 Core Income per Diluted Share of $4.69, up 14%,... Read more.
Pulsate Wins “New CUSO of the Year” at 2024 NACUSO Network Conference
DUBLIN–(BUSINESS WIRE)–Pulsate, provider of mobile-first engagement solutions that deepen digital banking relationships and cut through noise in consumers’... Read more.
Bowman Acquires MEP and Fire Protection Engineering Firm Moore Consulting Engineers
RESTON, Va.–(BUSINESS WIRE)–Bowman Consulting Group Ltd. (the “Company” or “Bowman”) (NASDAQ: BWMN), a national engineering services firm delivering... Read more.
KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024
MAHWAH, N.J.–(BUSINESS WIRE)–KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused... Read more.
Visa Reimagines Payment Acceptance for the ‘Click-and-Mortar’ Era
Visa Acceptance Solutions helps accelerate growth for merchants with new digital enablement offerings SAN FRANCISCO–(BUSINESS WIRE)–With a new fast-growing... Read more.
International Seaways, Inc. Announces Nomination of New Independent Directors
NEW YORK–(BUSINESS WIRE)–International Seaways, Inc. (NYSE: INSW) (“the Company” or “INSW”), one of the largest tanker companies worldwide providing... Read more.
BankUnited, Inc. Reports First Quarter 2024 Results
MIAMI LAKES, Fla.–(BUSINESS WIRE)–BankUnited, Inc. (the “Company”) (NYSE: BKU) today announced financial results for the quarter ended March 31,... Read more.
U.S. Bancorp Reports First Quarter 2024 Results
MINNEAPOLIS–(BUSINESS WIRE)–U.S. Bancorp reported its first quarter 2024 results today. The earnings release, earnings supplement and slide presentation... Read more.
Belgium International Remittance Business Report 2024: Market to Reach $24.64 Billion by 2028 – Analysis by Transaction Value & Volume, Transfers to and from Key States, Consumer Demographics – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Belgium International Remittance Market Business and Investment Opportunities – Analysis by Transaction Value... Read more.
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
– In the Phase 2 PRECEDENT Study, dalzanemdor (SAGE-718) did not show statistically significant differences versus placebo on the primary endpoint in patients... Read more.